drugset / Trial / NCT00958893

An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext

NCT00958893

Phase 2 Terminated 4 enrolled Repros Therapeutics Inc.
NaSingle-groupOpen-labelTreatment

Summary

An open label, extension study for subjects completing the ZPU-003 Ext 1 study.

Timeline

Start
2008-06
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Telapristone Acetate Other / unclassified 25 mg

Indications